Recent events have propelled biotech and pharmaceuticals into the global spotlight, demonstrating beyond doubt the ability of the sector to produce world-changing responses to critical healthcare challenges.
At the same time, there has been a rewriting of the rules. Cutting-edge technology is being developed and delivered at an unprecedented rate. Approaches to drug discovery have been rethought. Never-before-seen collaborations between pharmaceuticals, biotech and academia are now widespread. Clinical testing and regulatory approval have been accelerated, and we witnessed a mass vaccination programme becoming reality in a fraction of the time thought possible.
This resetting of the parameters brings opportunity for biotech and pharmaceuticals businesses, to develop new technologies, more rapidly than ever before. But it also makes new demands of those businesses. Expectations for delivery to the global market are intensifying, while funding requirements across the discovery and development are heavier for private equity and licensee partners.
For all of these reasons, the support of a legal adviser with broad, in-depth sector specialism is critical. And the Osborne Clarke biotech and pharmaceutical team brings expertise that spans both the scientific and commercial worlds. Possessing academic qualifications and hands-on industry experience, our Europe-wide network of lawyers has built its reputation providing co-ordinated advice to international clients across the sector, including those who support biotech and pharmaceuticals with services and technology.
From complex patent licensing, manufacturing and supply agreements, and technical regulatory advice, through to cross-border mergers and acquisitions, we can help you negotiate the many legal intricacies and emerging complexities you face today. More than that, our sector specialism can help you develop long-term strategic plans, built on the strongest possible legal foundations.
Advised Epitopea, a transatlantic cancer immunotherapeutics company and global leader in exploiting a new class of untapped tumour-specific antigens (TSAs), on their $13.6M (£10.3M) seed investment from a transatlantic syndicate of top-tier life sciences investors.
Advised Heqet Therapeutics, a King’s College biotech spin-out active in the field of regenerative medicine, on their £6.6m Series A financing round led by Claris Ventures and 2Invest.
Osborne Clarke has advised PharmaDrug, Inc. (Toronto, Canada) on its agreement dated May 31, 2022 with Khiron Life Sciences Corp. (Vancouver, Canada) to sell all of the outstanding shares in Pharmadrug Production GmbH, the company's wholly-owned German subsidiary.
Advised Bone Therapeutics, addressing high unmet medical needs in orthopaedics and bone diseases, on its €16 million loan financing from the European Investment Bank to support and prepare their lead asset, enhanced viscosupplement JTA-004, for future regulatory approval and commercialisation.
Advised NeRRe Therapeutics on its £20 million Series B2 financing round. The financing involved a syndicate of leading transatlantic life sciences investors led by new investor Columbus Venture Partners and existing investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed.
Advised global healthcare leader Grifols on the agreement with the Hong Kong’s Tiancheng International Investment Ltd. to acquire 100% of the shares of Tiancheng Pharmaceutical Holdings AG, which holds approximately a stake of 89.88% of Biotest ordinary shares and 1.08% of Biotest preferred shares for approximately EUR1.1bn.
Advised Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, on its $53 million (£38 million) Series B financing round.
Supported global pharmaceutical client Daiichi Sankyo on several new instructions in 2021/22, including significant matters involving the supply of drugs to the NHS.
Advised AviadoBio Ltd, a pioneering gene therapy company focused on developing and delivering transformative medicines for people living with neurodegenerative disorders, on its $80 million Series A financing round.
Advised on a series A investment in Belgian biotech company Univercells.
Advised the shareholders of First Water on its acquisition by Scapa Group for consideration of up to £15.3m payable depending on performance in 2016, 2017 and 2018.
Intrapharm Laboratories Ltd
Advised Intrapharm Laboratories Ltd management team and all of its shareholders on the disposal of the company to German pharmaceutical company RIEMSER Pharma GmbH.
Imperial Innovations Group plc
Advised Imperial Innovations Group plc and SV Life Sciences on a £19 million series A investment in Kesios Therapeutics.
Drug discovery company
Advised the shareholders of a privately held drug discovery company on its acquisition by C4X Discovery Holdings plc in exchange for shares in C4X.
Advised long-standing client LDC together with the management team on the sale of Penn Pharma in a transaction worth £127m.
Advised the syndicate of institutional investors, which included Imperial Innovations and Invesco Perpetual, on the £581m flotation of Circassia on the London Main Market.